Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELIS: Home Administration of Subcutaneous Trastuzumab
NCT01926886Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2013
- Primary completion
- Sep 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01926886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926886.